Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of ccRCC thrombus.

ABSTRACT: Proteomic analysis of ccRCC thrombus and tumors derived from patients.

INSTRUMENT(S): QE-HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Juntuo Zhou

PROVIDER: MSV000085727 | MassIVE | Sun Jul 12 19:04:00 BST 2020

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Secretome of Bone Marrow Stroma-Derived Neural Progenitor Cells: Proteomic Analysis

Project description:We found the bone marrow stromal-derived neural progenitor cells secretome have the neural protection effect. Proteomic analysis was performed nn order to analyze the protection factor in the secretome. Keywords: Neural protection, secretome

2008-10-18 | GSE13242 | GEO

Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.

Project description:Serum Proteomic Analysis of patients with Hidradenitis Suppurativa treated with Fostamatinib

2023-08-10 | GSE240607 | GEO

Clinical Proteomic Tumor Analysis Consortium (CPTAC)

Project description:Clinical Proteomic Tumor Analysis Consortium (CPTAC)

| PRJNA371289 | ENA

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

Project description:Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant adverse effect of paclitaxel in patients with breast cancer. However, reliable biomarkers for early detection and monitoring of CIPN are lacking.Methods: We investigated neurofilament light chain (NfL) and galectin-3 as candidate biomarkers for CIPN, and performed proteomic analysis to identify novel molecular contributors in two cohorts of patients with breast cancer undergoing paclitaxel therapy. Blood samples were collected longitudinally to measure NfL and galectin-3 levels. Differentially expressed proteins associated with CIPN onset were identified by proteomics.Results: NfL levels significantly increased in patients with CIPN, from as early as 3 weeks after treatment initiation. NfL levels were markedly higher in patients with vs. without CIPN. There were no changes or between-group differences in galectin-3 levels. Proteomic analysis identified upregulation of alcohol dehydrogenase 4 (ADH4) and downregulation of vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) in CIPN, implicating oxidative stress and disrupted mitochondrial dynamics in the pathogenesis of CIPN.Conclusion: NfL represents a candidate biomarker for early detection of CIPN, and we identified proteins potentially associated with the development of CIPN. Our findings provide further insights into the pathogenesis of CIPN. Integrating biomarkers and proteomics paves the way for precision medicine to manage chemotherapy-induced toxicities.

2026-06-16 | GSE315782 | GEO

Proteomic Comparison Of DSRCT, Normal Mesenteric Tissues and ES

Project description:Desmoplastic small round cell tumor (DSRCT) is an aggressive malignancy that occurs predominantly in young adult males and is characterized by abdominopelvic sarcomatosis exhibiting multi-lineage cellular nests of epithelial, muscular, mesenchymal, and neural differentiation admixed with desmoplastic stroma. Prior to the recognition of the disease as a distinct clinical entity, DSRCT was invariably misclassified as poorly differentiated atypical cancer of the testes, ovary, mesentery, or gastrointestinal tract, and the chemotherapies used for those malignancies elicited poor clinical response. As previously reported, a tectonic shift in the treatment of these patients occurred after researchers made two astute observations: 1) DSRCT microscopically resembles other small round “blue cell” sarcoma subtypes (e.g., ES, rhabdomyosarcoma, synovial sarcoma), and 2) DSRCT and ES have the same N-terminal EWSR1 fusion partner. Proteomic analysis using a reverse-phase protein lysate array (RPPA) was used to elucidate biomarkers that distinguish DSRCT from adjacent normal tissue and Ewing sarcoma. This proteomic analysis revealed novel proteins, such as the androgen receptor and Syk, that may be susceptible to drug targeting, as well as oncogenic pathways like Akt-PI3K that are highly expressed in DSRCT.

2020-12-31 | GSE108687 | GEO

Proteomic

Project description:Proteomic

2022-12-31 | OEX00021177 | NODE

Deep proteomic analysis of murine erythroid differentiation

Project description:Deep proteomic analysis of murine erythroid differentiation

| PRJNA492908 | ENA

Integrative Genomic and Proteomic Analysis of Prostate Cancer Reveals Signatures of Metastatic Progression

Project description:An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed revealing only 48-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors. Keywords: prostate cancer progression

2005-09-20 | GSE3325 | GEO

Identification of BBOX1 binding partners using AP-MS in ccRCC tumors

Project description:Gamma-Butyrobetaine Hydroxylase 1 (BBOX1) is a 2-OG dependent enzyme evolving in carnitine synthesis and lipid metabolism. In this study, we propose BBOX1 is a potential tumor suppressor in kidney cancer. We found that BBOX1 is generally underexpressed in ccRCC cells and patients. Restore BBOX1 in ccRCC cells suppresses tumor growth in multiple xenograft mouse models. To understand the potential mechanism, we plan to perform IP-Mass spec analysis in the cell-derived xenograft tumors with or without BBOX1 expression to identify novel binding partners which mediate the tumor suppressive role of BBOX1 in ccRCC.

2024-12-23 | PXD050455 | Pride

Proteomic analysis of advanced clear cell renal cell carcinoma

Project description:Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. Advanced kidney cancer has a high chance of recurrence and metastasis after surgery. This project performed proteomic analysis on advanced ccRCC tumor samples to describe the molecular landscape of advanced tumors.

2025-01-02 | PXD059367 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data